Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Nautilus Biotechnology Inc shares valued at $11,488 were purchased by Mowry Anna on May 29 ’25. At $0.77 per share, Mowry Anna acquired 15,000 shares. The insider’s holdings grew to 83,000 shares worth approximately $58930.0 following the completion of this transaction.
Also, Mallick Parag purchased 12,000 shares, netting a total of over 8,788 in proceeds. Following the buying of shares at $0.73 each, the insider now holds 20,491,892 shares.
Before that, Mallick Parag had added 1,500 shares to its account. In a trade valued at $1,098, the Chief Scientist bought Nautilus Biotechnology Inc shares for $0.73 each. Upon closing the transaction, the insider’s holdings increased to 1,500 shares, worth approximately $14.55 million.
As published in a research note from Goldman on December 05, 2024, Nautilus Biotechnology Inc [NAUT] has been rated down from a Neutral to a Sell and the price target has been revised to $1.75. Analysts at Guggenheim started covering the stock with ‘”a Buy”‘ outlook in a report released in late June. Earlier on January 06, 2022, Morgan Stanley initiated its rating. Their recommendation was “an Equal-weight” for NAUT stock.
Analyzing NAUT Stock Performance
On last trading session,, Nautilus Biotechnology Inc [NASDAQ: NAUT] rose 1.06% to $0.71. During the last five days, there has been a drop of approximately -2.34%. Over the course of the year, Nautilus Biotechnology Inc shares have dropped approximately -57.86%. Shares of the company reached a 52-week high of $2.1100 on 01/21/25 and a 52-week low of $0.6600 on 05/05/25.
Support And Resistance Levels for Nautilus Biotechnology Inc (NAUT)
According to the 24-hour chart, there is a support level at 0.6760, which, if violated, would cause prices to drop to 0.6440. In the upper region, resistance lies at 0.7440. The next price resistance is at 0.7800. RSI (Relative Strength Index) is 43.64 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Nautilus Biotechnology Inc (NAUT)?
In terms of Nautilus Biotechnology Inc share price expectations, FactSet research, analysts set an average price target of 2.5 in the next 12 months, up nearly 257.14% from the previous closing price of $0.70. Analysts anticipate Nautilus Biotechnology Inc stock to reach 2.5 by 2025, with the lowest price target being 2.5. In spite of this, 3 analysts ranked Nautilus Biotechnology Inc stock as Buy at the end of 2025.
